´¡±ô³ú³ó±ð¾±³¾±ð°ù’s /newsroom/taxonomy/term/8535/all en Mark Brandon /newsroom/mark-brandon Mon, 20 Mar 2023 20:53:16 +0000 shirley.cardenas@mcgill.ca 297093 at /newsroom KalGene gears up to manufacture and test promising ´¡±ô³ú³ó±ð¾±³¾±ð°ù’s treatment with NRC, ±«ÓãÖ±²¥ and CIMTEC /newsroom/channels/news/kalgene-gears-manufacture-and-test-promising-alzheimers-treatment-nrc-mcgill-and-cimtec-263196 <div> <div> <div> <p>KalGene Pharmaceuticals and the National Research Council of Canada (NRC) are proud to announce the signature of an agreement worth over $1M to develop, scale up, and transfer the technology needed to manufacture a promising novel ´¡±ô³ú³ó±ð¾±³¾±ð°ù’s treatment in Canada that the parties have been co- developing since 2015.</p> <p>The treatment, a biologic molecule made up of a peptide that fights ´¡±ô³ú³ó±ð¾±³¾±ð°ù’s and an antibody-based carrier molecule designed to shuttle the peptide into the brain, is a custom- engineered therapeutic developed at NRC.</p></div></div></div> Mon, 03 Oct 2016 16:20:08 +0000 priya.pajel@mail.mcgill.ca 26232 at /newsroom